SCHEMBL17456046

SCHEMBL17456046

c1ccc(CN2CCC(Oc3cccnc3-c3ccncc3)C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 2/20 0.53
▸ CYP11B1 P15538 1/20 0.50
▸ CYP11B2 P19099 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ROCK1 Q13464 4/20 0.47
▸ ROCK2 O75116 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ SCN9A Q15858 1/20 0.45
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ SCN8A Q9UQD0 6/20 0.43
▸ SCN1A P35498 2/20 0.43
▸ GMNN O75496 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ DRD2 P14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455968 0.93 SMN1; SMN2 (0.53) MCHR1CYP11B1CYP11B2ROCK1ROCK2
SCHEMBL17455988 0.84 KDM4E (0.46) CYP11B1CYP11B2KDM4ESMN1; SMN2SCN9A
SCHEMBL17456050 0.84 SCN9A (0.49) CYP11B1CYP11B2KDM4ESMN1; SMN2SCN9A
SCHEMBL7468135 0.84 MCHR1 (0.53) MCHR1KDM4ENPC1L3MBTL1SMN1; SMN2
SCHEMBL17456049 0.82 MCHR1 (0.57) MCHR1KDM4ENPC1L3MBTL1ROCK1
SCHEMBL17456021 0.82 SCN9A (0.43) CYP11B1CYP11B2SMN1; SMN2SCN9ASCN8A
SCHEMBL17455921 0.81 CYP11B1 (0.42) CYP11B1CYP11B2SMN1; SMN2SCN9ASCN8A
SCHEMBL17456026 0.81 HRH3 (0.54) SMN1; SMN2CYP3A4CYP2D6
SCHEMBL17455954 0.81 ALDH1A1 (0.48) CYP11B1CYP11B2KDM4ENPC1L3MBTL1
SCHEMBL17456041 0.81 CYP11B1 (0.53) MCHR1CYP11B1CYP11B2ROCK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 MCHR1 2123/4885CYP11B1 88/4885CYP11B2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback